Results 51 to 60 of about 264,423 (290)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane, Giorgia Coratti, Chiara Cutrì, Antonio Varone, Riccardo Masson, Adele D'Amico, Valeria Sansone, Sonia Messina, Federica Ricci, Chiara Ticci, Claudio Bruno, Caterina Agosto, Francesca Benedetti, Antonella Pini, Sabrina Siliquini, Massimiliano Filosto, Alberto Zambon, Ilaria Bitetti, Maria Rosaria Manna, Claudia Dosi, Riccardo Zanin, Stefano Parravicini, Roberto De Sanctis, Giulia Stanca, Michela Catteruccia, Michele Tosi, Irene Mizzoni, Emilio Albamonte, Valentina Franchino, Maria Sframeli, Ilaria Cavallina, Elena Procopio, Michele Sacchini, Simone Morando, Noemi Brolatti, Federica Trucco, Gaia Scarpini, Elena Briganti, Beatrice Berti, Concetta Palermo, Daniela Leone, Stefano C. Previtali, Eugenio Mercuri, the ITASMAC working group   +43 more
wiley   +1 more source

Limitations in the recording of maternal mortality in Germany: An analysis of statistical challenges [PDF]

Journal of Health Monitoring
Background: The World Health Organization (WHO) defines maternal mortality as the death of a woman during pregnancy or up to 42 days after delivery. The maternal mortality ratio (MMR) serves as an indicator of the quality of health care.
Safiya Fatima Zaloum, Julia Callaghan, Amira Goepfrich, Joachim Dudenhausen, Lars Paulson, Lars Hellmeyer, Klaus Vetter, Martina Ziegert, Thorsten Braun, Josefine Theresia Koenigbauer   +9 more
doaj   +1 more source

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

Evaluation of Errors on Death Certificates

Journal of Nepal Health Research Council
Background: Death certificates provide vital data for disease surveillance and health policy. However, errors are common globally, undermining data reliability.
Alok Atreya, Bina Acharya, Purushottam Prasad Yadav, Ritesh G Menezes, Samata Nepal   +4 more
doaj   +1 more source

Reforming death certification [PDF]

BMJ, 2006
EDITOR—The government has cited cost and bureaucracy as reasons for not reforming death certification, as recommended by the Luce report and by Dame Janet Smith's report into the Shipman affair. …
openaire   +2 more sources

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak, Marije M. C. Voermans, Hans Heijst, Charlotte E. Teunissen, Marc Engelen   +4 more
wiley   +1 more source

Inadequacies of death certification in Beirut: who is responsible?

Bulletin of the World Health Organization
OBJECTIVE: To assess the completeness of data on death certificates over the past 25 years in Beirut, Lebanon, and to examine factors associated with the absence of certifiers' signatures and the non-reporting of the underlying cause of death. METHODS: A
Abla M. Sibai, Iman Nuwayhid, May Beydoun, Monique Chaaya   +3 more
doaj   +1 more source

Causes of mortality for Indonesian Hajj Pilgrims: comparison between routine death certificate and verbal autopsy findings. [PDF]

PLoS ONE, 2013
BACKGROUND: Indonesia provides the largest single source of pilgrims for the Hajj (10%). In the last two decades, mortality rates for Indonesian pilgrims ranged between 200-380 deaths per 100,000 pilgrims over the 10-week Hajj period.
Masdalina Pane, Sholah Imari, Qomariah Alwi, I Nyoman Kandun, Alex R Cook, Gina Samaan   +5 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Insights on dying, dementia and death certificates

Archives of Public Health, 2018
For our master thesis in medicine, we aimed to determine how many deaths were caused by and with dementia in 2014 and we compared our results with figures from abroad.
Sofie Vandormael, Alexander Meirschaert, Jan Steyaert, Jan De Lepeleire   +3 more
doaj   +1 more source